Woong Bi Jang1,2, Seung Taek Ji1,2, Ji Hye Park1,2, Yeon-Ju Kim1,2, Songhwa Kang1,2, Da Yeon Kim1,2, Na-Kyung Lee1,2, Jin Su Kim1,2, Hye Ji Lim1,2, Jaewoo Choi1,2, Thi Hong Van Le1,2, Thanh Truong Giang Ly1,2, Vinoth Kumar Rethineswaran1,2, Dong Hwan Kim3, Jong Seong Ha1,2, Jisoo Yun1,2, Sang Hong Baek4, Sang-Mo Kwon5,6,7. 1. Laboratory of Regenerative Medicine and Stem Cell Biology, Department of Physiology, Medical Research Institute, School of Medicine, Pusan National University, 20 Geumo-ro, Mulgeum-eup, Yangsan, 50612, Republic of Korea. 2. Research Institute of Convergence Biomedical Science and Technology, Pusan National University School of Medicine, 20 Geumo-ro, Mulgeum-eup, Yangsan, 50612, Republic of Korea. 3. Department of Neurosurgery & Medical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan, 49241, Republic of Korea. 4. Division of Cardiology, Seoul St. Mary's Hospital, School of Medicine, the Catholic University of Korea, 505, Banpo-dong, Seocho-gu, Seoul, 06591, Republic of Korea. whitesh@catholic.ac.kr. 5. Laboratory of Regenerative Medicine and Stem Cell Biology, Department of Physiology, Medical Research Institute, School of Medicine, Pusan National University, 20 Geumo-ro, Mulgeum-eup, Yangsan, 50612, Republic of Korea. smkwon323@hotmail.com. 6. Research Institute of Convergence Biomedical Science and Technology, Pusan National University School of Medicine, 20 Geumo-ro, Mulgeum-eup, Yangsan, 50612, Republic of Korea. smkwon323@hotmail.com. 7. Laboratory for Vascular Medicine and Stem Cell Biology, Department of Physiology, Medical Research Institute, School of Medicine, Pusan National University, 20 Geumo-ro, Mulgeum-eup, Yangsan, 50612, Republic of Korea. smkwon323@hotmail.com.
Abstract
BACKGROUND: Despite promising advances in stem cell-based therapy, the treatment of ischemic cardiovascular diseases remains a big challenge due to both the insufficient in vivo viability of transplanted cells and poor angiogenic potential of stem cells. The goal of this study was to develop therapeutic human cardiac progenitor cells (hCPCs) for ischemic cardiovascular diseases with a novel M13 peptide carrier. METHOD: In this study, an engineered M13 peptide carrier was successfully generated using a QuikChange Kit. The cellular function of M13 peptide carrier-treated hCPCs was assessed using a tube formation assay and scratch wound healing assay. The in vivo engraftment and cell survival bioactivities of transplanted cells were demonstrated by immunohistochemistry after hCPC transplantation into a myocardial infarction animal model. RESULTS: The engineered M13RGD+SDKP peptide carrier, which expressed RGD peptide on PIII site and SDKP peptide on PVIII site, did not affect morphologic change and proliferation ability in hCPCs. In contrast, hCPCs treated with M13RGD+SDKP showed enhanced angiogenic capacity, including tube formation and migration capacity. Moreover, transplanted hCPCs with M13RGD+SDKP were engrafted into the ischemic region and promoted in vivo cell survival. CONCLUSION: Our present data provides a promising protocol for CPC-based cell therapy via short-term cell priming of hCPCs with engineered M13RGD+SDKP before cell transplantation for treatment of cardiovascular disease.
BACKGROUND: Despite promising advances in stem cell-based therapy, the treatment of ischemic cardiovascular diseases remains a big challenge due to both the insufficient in vivo viability of transplanted cells and poor angiogenic potential of stem cells. The goal of this study was to develop therapeutic human cardiac progenitor cells (hCPCs) for ischemic cardiovascular diseases with a novel M13 peptide carrier. METHOD: In this study, an engineered M13 peptide carrier was successfully generated using a QuikChange Kit. The cellular function of M13 peptide carrier-treated hCPCs was assessed using a tube formation assay and scratch wound healing assay. The in vivo engraftment and cell survival bioactivities of transplanted cells were demonstrated by immunohistochemistry after hCPC transplantation into a myocardial infarction animal model. RESULTS: The engineered M13RGD+SDKP peptide carrier, which expressed RGD peptide on PIII site and SDKP peptide on PVIII site, did not affect morphologic change and proliferation ability in hCPCs. In contrast, hCPCs treated with M13RGD+SDKP showed enhanced angiogenic capacity, including tube formation and migration capacity. Moreover, transplanted hCPCs with M13RGD+SDKP were engrafted into the ischemic region and promoted in vivo cell survival. CONCLUSION: Our present data provides a promising protocol for CPC-based cell therapy via short-term cell priming of hCPCs with engineered M13RGD+SDKP before cell transplantation for treatment of cardiovascular disease.
Authors: A Kawamoto; H C Gwon; H Iwaguro; J I Yamaguchi; S Uchida; H Masuda; M Silver; H Ma; M Kearney; J M Isner; T Asahara Journal: Circulation Date: 2001-02-06 Impact factor: 29.690
Authors: Junping Sun; Jia Zhang; Wen Yan; Cai Chen; Geru Wu; Shahrzad Abbasi; Bao Pham; Steven Lee; Jie Cheng; Nada B Memon; Yutao Xi Journal: Int J Cardiol Date: 2014-07-12 Impact factor: 4.164
Authors: Shuning Zhang; Xiuchun Li; Frances L Jourd'heuil; Shunlin Qu; Neil Devejian; Edward Bennett; David Jourd'heuil; Chuanxi Cai Journal: Sci Rep Date: 2017-09-07 Impact factor: 4.379